FDA started Initiative for DUNS Numbers of Pharmaceutical Sites
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
In our News from 4 September 2013, we reported about the DUNS numbers for the identification of pharmaceutical sites in Site Master Files. Usually, this applies only to companies which are located outside the EU/EEA.
Last year, the FDA also started an initiative for the DUNS numbers of companies which have to provide information about the location of their facilities to the FDA. These companies may therefore be contacted by Dun & Bradstreet personnel. According to the FDA there is no legal requirement for companies to collaborate. Nevertheless, the FDA asks for cooperation with the registration.
Please see the FDA's information entitled "Dun and Bradstreet Verification" for the details.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years